Skip to main content

Table 1 Clinicopathological characteristics of node negative breast cancer patients from the Mainz cohort with available gene array and COX-2 immunostaining data (n = 193)

From: Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients

Characteristics n %
Age at diagnosis   
<50 44 22.8
≥50 149 77.2
pT stage   
pT1 105 54.4
pT2 85 44.0
pT3 3 1.6
Histological grade   
G I 41 21.2
G II 105 54.4
G III 47 24.4
Estrogen receptor status   
Negative 45 23.3
Positive 148 76.7
Progesterone receptor status   
Negative 81 42.0
Positive 112 58.0
Hormone receptor status 1   
Negative 39 20.2
Positive 154 79.8
HER-2 status   
Negative 167 86.5
Positive 26 13.5
Death   
Of cancer 30 15.5
Unrelated to cancer 25 12.9
Surviving 138 71.5
Relapse 57 29.5
Regional 21 10.9
Metastasis 44 22.8
Contralateral 5 2.6
No relapse 136 70.5
COX-2 intensity score (IS)   
  0 35 18.1
  1 45 23.2
  2 65 33.7
  3 48 24.9
COX-2 proportion score (PS)   
  0 35 18.1
  1 24 12.4
  2 42 21.8
  3 33 17.1
  4 59 30.6
COX-2 immunostaining score (product of IS and PS)   
  0 35 18.1
  1 11 5.7
  2 22 11.4
  3 16 8.3
  4 30 15.5
  6 20 10.4
  8 23 11.9
  9 9 4.7
  12 27 14.0
COX-2 immunostaining status   
  Negative 145 75.1
  Positive 48 24.9
  1. 1The hormone receptor status is positive as soon as one of both, the estrogen or the progesterone receptor status, is positive.